+49 152 22 82 97 73
 

Publications

Fulltext publications MArS Team chronological listing

Walzer S, Droeschel D, Vollmer LM, Atkin L, Ousey K 

A cost-effectiveness analysis of a hydration response technology dressing in the treatment of venous leg ulcers in the UK 

Journal of Wound Care. 2018. Mar(2); 27(3): 166-172

Droeschel D, Gutknecht M, Walzer S, Lindsay F, Shannon R, Augustin M 

Eine probabilistische Kosteneffektivitätsanalyse einer azellulären synthetischen Matrix (ASM) als Ergänzung zur Standardversorgung venöser und gemischter Ulzera curtis in Deutschland auf Basis eines Discrete-Event-Simulations-Modells [A probabilistic cost-effectiveness analysis of an acellular synthetic matrix (ASM) as a supplement to standard of care of venous and mixed leg ulcers in Germany based on a discrete event simulation model]

Gesundheitsökonomie und Qualitätsmanagement. 2017. 1-13

Walzer S, Gutknecht M, Lindsay F, Droeschel D, Augustin M 

Ein Discrete-Event Simulationsmodell zur Abbildung von Verläufen chronischer Wunden in Deutschland: Die methodischen Grundlagen [A discrete-event simulation model for chronic wounds in Germany: The methodological basis]

German Journal of ClinicoEconomics. 2016. 13-23

Walzer S, Gerber-Grothe A, John J, Rogowski W 

Vergütungshöhe und Preissetzung [Reimbursement level and pricing]

in Rogowski W. Business Planning im Gesundheitswesen. Springer Gabler. 2016. Chapter 9. 205 - 234

Ponzetti C, Canciani M, Farina M, Era S, Walzer S 

Administrative risk quantification of subcutaneous and intravenous therapies in Italian centers utilizing the Failure Mode and Effects Analysis approach

ClinicoEconomics and Outcomes Research. 2016. 8: 353-359  

Ponzetti C, Canciani M, Farina M, Era S, Walzer S 

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey

ClinicoEconomics and Outcomes Research. 2016. 8: 227-233  

Walzer S, Storck M, Droeschel D. 

Eine Kosten-Effektivitätsanalyse der Behandlung des Ulkus cruris venosum und mixtum in Deutschland mit Flaminal. [A cost-effectiveness analysis for the treatment in venous leg ulcer in Germany with Flaminal]

German Journal of ClinicoEconomics. 2016. 1: 1-12 

Walzer S, Chouaid C, Lister J, Gultyaev D, Vergnenegre A, de Marinis F, Meng J, de Castro Carpeno J, Crott R, Kleman M, Ngoh C. 

Simulation and comparison of progression-free survival among patients with non-squamous non-small cell lung cancer receiving sequential therapy. 

Expert Rev Anticancer There. 2015 Jan; 15(1): 121-128 dii: 10.1586/14737140.2015.961428. Epub 2014 Sep 24


Schwander D, Banz K, Kaier K, Walzer S 
Evaluation of a possible predictor for Federal Joint Committee decisions on early benefit assessments according to the German act on the reform of the market for medicinal product 
Health Policy 2014 Sept; 117(3): 334-344

Walzer S, Droeschel D 

Sind Unvollständigkeiten vermeidbar? [Is incompleteness in the context of AMNOG avoidable?] 
Market Access & Health Policy 2014; 6: 16-18


Walzer S, Droeschel D, Nuijten M, Chevrou-Séverac H.
Health economics evidence for medical nutrition: are these interventions value for money in integrated care?
ClinicoEconomics and Outcomes Research 2014; 6: 241-252

Walzer S, Droeschel D.
Mischpreise im Kontext des AMNOG [Mixed pricing in the context of AMNOG]
.
Market Access & Health Policy 2014; 3: 23-25

Walzer S, Droeschel D, Nuijten M, Chevrou-Séverac H.
Health economic analyses in medical nutrition: a systematic literature review
.
ClinicoEconomics and Outcomes Research 2014; 6: 109-124

Rautenberg T, Siebert U, Arnold D, Bennouna J, Kubicka S, Walzer S, Ngoh C.
Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer
.
Journal of Medical Economics 2013. 1-12

Walzer S, Annemans L, Parow D, Zoellner Y, Shekarriz S, Antonanzas F.
The German AMNOG and its current potential implications on the Spanish and Belgian pricing and reimbursement decisions
.
Journal of Health Policy and Outcomes Research 2013. doi: 10.7365/JHPOR.2013.3.6

Walzer S, Kogels E, Schwander B, Nuijten M.
Pharmaceutical premium price strategy: what could be applied by the medical nutrition industry?

Agro FOOD Industry Hi Tech, Vol. 24(2) - March/April 2013: 39-43

Grossi F, Genova C, Gaitan ND, Dal Bello MG, Rijavec E, Barletta G, Sini C, Donato C, Beltramini S, Pronzato P, Porcile G, Boccardo F, Walzer S.
Free drugs in clinical trials and their potential cost saving impact on the National Health Service: A retrospective cost analysis in Italy
.
Lung Cancer. 2013. doi:10.1016/j.lungcan.2013.03.021

Walzer S, Travers K, Rieder S, Erazo-Fischer E, Matusiewicz D.
Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey
.
Clinico Economics and Outcomes Research. 2013; 5: 189 - 192

Juhász E, Kim J-H, Klingelschmitt G, Walzer S.
Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer
.
European Journal of Cancer. 2013. http://dx.doi.org/10.1016/j.ejca.2012.11.006

Walzer S, Nuijten M, Wiesner C, Kaier K, Johansson P-O, Oertel S.
Microeconomic surplus in healthcare: Applied economic theory in healthcare in four European countries.

Front. Pharmacol. 2013; 4:17. doi:10.3389/fphar.2013.00017

Lister J, Stanisic S, Kaier K, Hagist C, Gultyaev D, Walzer S.
Societal savings in advanced non-squamous non-small cell lung cancer (NSCLC) in France, Germany, Italy, and Spain in patients treated with bevacizumab-based versus non-bevacizumab-based treatments
.
ClinicoEconomics and Outcomes Research. 2012; 4: 299-305

Walleser S, Ray J, Bischoff H, Vergnenègre A, Rosery H, Chouaid C, Heigener D, de Castro Carpeño J, Tiseo M, Walzer S.
Maintenance erlotinib in advanced non-small cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
.
ClinicoEconomics and Outcomes Research. 2012; 4: 269-275

Schwander B, Ravera S, Giuliani G, Nuijten M, Walzer S.
Cost comparison of second-line treatment options for late stage non-small cell lung cancer: cost analysis for Italy
.
ClinicoEconomic and Outcomes Research. 2012; 4: 237-243

Vergnenègre A, Ray JA, Chouaid C, Grossi F, Bischoff HG, Heigener DF, Walzer S.
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer.

Clinicoecon Outcomes Res. 2012;4:31-7. Epub 2012 Jan 26.

Nuijten MJ, de Castro Carpeño J, Chouaid C, Vergnenègre A, Grossi F, Bischoff H, Heigener D, Walzer S.
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.

Lung Cancer. 2012 Jun;76(3):465-71. Epub 2011 Dec 5.

Nuijten MJ, Aultman R, Carpeño Jde C, Vergnenègre A, Chouaid C, Walzer S, Siebert U.
An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.

Curr Med Res Opin. 2011 Nov; 27(11): 2193-201. Epub 2011 Oct 4

de Castro Carpeño J, Castro Gómez AJ, Stanisic S, Walzer S.
Is there Value in Using Bevacizumab in Metastatic Non-Small Cell Lung Cancer?

Cancer & Chemotherapy Rev. 2011;6 (3)

Chang GC, Ahn MJ, Wright E, Kim HT, Kim JH, Kang JH, Kim SW, Sherman S, Walzer S.
Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes.

Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:34-40

Ahn MJ, Tsai CM, Hsia TC, Wright E, Chang JW, Kim HT, Kim JH, Kang JH, Kim SW, Bae EJ, Kang M, Lister J, Walzer S.
Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan.

Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:22-33

Chang JW, Thongprasert S, Wright E, Tsang K, Kim HT, Ahn MJ, Kim JH, Kang JH, Kim SW, Walzer S.
An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia.

Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:13-21

Banz K, Bischoff H, Brunner M, Chouaid C, de Castro Carpeño J, de Marinis F, Grossi F, Vergnenègre A, Walzer S.
Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.
Lung Cancer. 2011 Dec;74(3):529-34. Epub 2011 May 17.

Mickisch GH, Schwander B, Escudier B, Bellmunt J, Maroto P, Porta C, Walzer S, Siebert U:
Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy
;
Clinicoecon Outcomes Res. 2011;3:19-27. Epub 2011 Jan 25.

Nuijten M, Heigener DF, Bischoff HG, Chouaid C, Vergnenègre A, de Castro Carpeño J, Aultman R, Walzer S, Siebert U.
Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer.

Lung Cancer. 2010 Aug;69 Suppl 1:S4-10. Erratum in: Lung Cancer. 2010 Nov;70(2):230. Lung Cancer. 2010 Aug;69 Suppl 1:S31.

Stanisic S, Bischoff HG, Heigener DF, Vergnenègre A, de Castro Carpeño J, Chouaid C, Walzer S, Mueller E, Schmidt E.
Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC).

Lung Cancer. 2010 Aug;69 Suppl 1:S24-30.

Bischoff HG, Heigener DF, Walzer S, Nuijten M.
Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany.

Lung Cancer. 2010 Aug;69 Suppl 1:S18-23.

Giuliani G, Grossi F, de Marinis F, Walzer S.
Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy.

Lung Cancer. 2010 Aug;69 Suppl 1:S11-7

Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M.
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.

Br J Cancer. 2010 Jan 5;102(1):80-6. Epub 2009 Nov 17.

Mueller E, Walzer S, Krone F-A, Fassbinder W.
Kosteneinsparung in der Behandlung der renalen Anämie durch subkutane Applikation von Epoetin beta
.
[Cost savings in renal anemia through subcutaneous administration of epoetin beta]. Nieren- und Hochdruckkrankheiten, 37, 8/2008: 404-411

Walzer S.
What do parents want from their child's asthma treatment?
Ther Clin Risk Manag. 2007 Mar;3(1):167-75.

Walzer S, Zweifel P.
Willingness-to-pay for caregivers of children with asthma or wheezing conditions.

Ther Clin Risk Manag. 2007 Mar;3(1):157-65.

Janka HU, Hessel F, Walzer S, Mueller E.
Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes - a simulation with the Diabetes Mellitus Model (DMM).

Int J Clin Pharmacol Ther. 2007 Dec;45(12):623-30.

Hitchcock W, Mellon M, Memran M, Parasuraman B, Ramachandran S, Walzer S.
Caregiver preferences for pediatric asthma treatment delivery systems.
Adv Ther. 2007 Nov-Dec;24(6):1240-53.

The Mount Hood 4 Modeling Group.
Computer Modeling of Diabetes and Its Complications. A report on the Fourth Mount Hood Challenge Meeting.
Diabetes Care. 2007; 30:1638-1646

Walzer S.
Early retirement and the influence on healthcare budgets and insurance premiums in a diabetes population.

Vasc Health Risk Manag. 2007;3(3):331-41.

Mueller E, Maxion-Bergemann S, Gultyaev D, Walzer S, Freemantle N, Mathieu C, Bolinder B, Gerber R, Kvasz M, Bergemann R.
Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model.

Diabetes Technol Ther. 2006 Apr;8(2):219-36.

Casciano RN, Walzer S, Mueller E.
Krankheitsmodell am Beispiel Diabetes - das EAGLE-Modell

[Eagle - an example for a diabetes simulation model]. Gesund.ökon. Qual manag Supplement 2, 2005; 10: S64-S69

 

Fulltext publications MArS Team topic related listing

Health Economics / Modelling

Walzer S, Droeschel D, Vollmer LM, Atkin L, Ousey K 

A cost-effectiveness analysis of a hydration response technology dressing in the treatment of venous leg ulcers in the UK 

Journal of Wound Care. 2018. Mar(2); 27(3): 166-172

Droeschel D, Gutknecht M, Walzer S, Lindsay F, Shannon R, Augustin M 

Eine probabilistische Kosteneffektivitätsanalyse einer azellulären synthetischen Matrix (ASM) als Ergänzung zur Standardversorgung venöser und gemischter Ulzera curtis in Deutschland auf Basis eines Discrete-Event-Simulations-Modells [A probabilistic cost-effectiveness analysis of an acellular synthetic matrix (ASM) as a supplement to standard of care of venous and mixed leg ulcers in Germany based on a discrete event simulation model]

Gesundheitsökonomie und Qualitätsmanagement. 2017. 1-13

Walzer S, Gutknecht M, Lindsay F, Droeschel D, Augustin M 

Ein Discrete-Event Simulationsmodell zur Abbildung von Verläufen chronischer Wunden in Deutschland: Die methodischen Grundlagen [A discrete-event simulation model for chronic wounds in Germany: The methodological basis]

German Journal of ClinicoEconomics. 2016. 13-23

Ponzetti C, Canciani M, Farina M, Era S, Walzer S 

Administrative risk quantification of subcutaneous and intravenous therapies in Italian centers utilizing the Failure Mode and Effects Analysis approach

ClinicoEconomics and Outcomes Research. 2016. 8: 353-359

Ponzetti C, Canciani M, Farina M, Era S, Walzer S 

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey

ClinicoEconomics and Outcomes Research. 2016. 8: 227-233  

Walzer S, Storck M, Droeschel D. 

Eine Kosten-Effektivitätsanalyse der Behandlung des Ulkus cruris venosum und mixtum in Deutschland mit Flaminal. [A cost-effectiveness analysis for the treatment in venous leg ulcer in Germany with Flaminal]

German Journal of ClinicoEconomics. 2016. 1: 1-12

Walzer S, Chouaid C, Lister J, Gultyaev D, Vergnenegre A, de Marinis F, Meng J, de castro Carpeno J, Crott R, Kleman M, Ngoh C. 

Simulation and comparison of progression-free survival among patients with non-squamous non-small cell lung cancer receiving sequential therapy. 

Expert Rev Anticancer There. 2015 Jan; 15(1): 121-128 dii: 10.1586/14737140.2015.961428. Epub 2014 Sep 24


Rautenberg T, Siebert U, Arnold D, Bennouna J, Kubicka S, Walzer S, Ngoh C.
Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer.
Journal of Medical Economics 2013. 1-12

Grossi F, Genova C, Gaitan ND, Dal Bello MG, Rijavec E, Barletta G, Sini C, Donato C, Beltramini S, Pronzato P, Porcile G, Boccardo F, Walzer S.
Free drugs in clinical trials and their potential cost saving impact on the National Health Service: A retrospective cost analysis in Italy
.
Lung Cancer. 2013. doi:10.1016/j.lungcan.2013.03.021

Lister J, Stanisic S, Kaier K, Hagist C, Gultyaev D, Walzer S.
Societal savings in advanced non-squamous non-small cell lung cancer (NSCLC) in France, Germany, Italy, and Spain in patients treated with bevacizumab-based versus non-bevacizumab-based treatments
.
ClinicoEconomics and Outcomes Research. 2012; 4: 299-305

Walleser S, Ray J, Bischoff H, Vergnenègre A, Rosery H, Chouaid C, Heigener D, de Castro Carpeño J, Tiseo M, Walzer S.
Maintenance erlotinib in advanced non-small cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
.
ClinicoEconomics and Outcomes Research. 2012; 4: 269-275

Schwander B, Ravera S, Giuliani G, Nuijten M, Walzer S.
Cost comparison of second-line treatment options for late stage non-small cell lung cancer: cost analysis for Italy
.
ClinicoEconomic and Outcomes Research. 2012; 4: 237-243

Vergnenègre A, Ray JA, Chouaid C, Grossi F, Bischoff HG, Heigener DF, Walzer S.
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer.

Clinicoecon Outcomes Res. 2012;4:31-7. Epub 2012 Jan 26.

Nuijten MJ, de Castro Carpeño J, Chouaid C, Vergnenègre A, Grossi F, Bischoff H, Heigener D, Walzer S.
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.

Lung Cancer. 2012 Jun;76(3):465-71. Epub 2011 Dec 5.

de Castro Carpeño J, Castro Gómez AJ, Stanisic S, Walzer S.
Is there Value in Using Bevacizumab in Metastatic Non-Small Cell Lung Cancer?
Cancer & Chemotherapy Rev. 2011;6 (3)

Ahn MJ, Tsai CM, Hsia TC, Wright E, Chang JW, Kim HT, Kim JH, Kang JH, Kim SW, Bae EJ, Kang M, Lister J, Walzer S.
Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan.

Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:22-33

Banz K, Bischoff H, Brunner M, Chouaid C, de Castro Carpeño J, de Marinis F, Grossi F, Vergnenègre A, Walzer S.
Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.

Lung Cancer. 2011 Dec;74(3):529-34. Epub 2011 May 17.

Stanisic S, Bischoff HG, Heigener DF, Vergnenègre A, de Castro Carpeño J, Chouaid C, Walzer S, Mueller E, Schmidt E.
Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC).

Lung Cancer. 2010 Aug;69 Suppl 1:S24-30.

Bischoff HG, Heigener DF, Walzer S, Nuijten M.
Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany.

Lung Cancer. 2010 Aug;69 Suppl 1:S18-23.

Giuliani G, Grossi F, de Marinis F, Walzer S.
Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy.

Lung Cancer. 2010 Aug;69 Suppl 1:S11-7

Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M.
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.

Br J Cancer. 2010 Jan 5;102(1):80-6. Epub 2009 Nov 17.

Mueller E, Walzer S, Krone F-A, Fassbinder W.
Kosteneinsparung in der Behandlung der renalen Anämie durch subkutane Applikation von Epoetin beta
.
[Cost savings in renal anemia through subcutaneous administration of epoetin beta]. Nieren- und Hochdruckkrankheiten, 37, 8/2008: 404-411

Janka HU, Hessel F, Walzer S, Mueller E.
Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes - a simulation with the Diabetes Mellitus Model (DMM).
Int J Clin Pharmacol Ther. 2007 Dec;45(12):623-30.

The Mount Hood 4 Modeling Group.
Computer Modeling of Diabetes and Its Complications. A report on the Fourth Mount Hood Challenge Meeting
.
Diabetes Care. 2007; 30:1638-1646

Walzer S.
Early retirement and the influence on healthcare budgets and insurance premiums in a diabetes population.

Vasc Health Risk Manag. 2007;3(3):331-41.

Mueller E, Maxion-Bergemann S, Gultyaev D, Walzer S, Freemantle N, Mathieu C, Bolinder B, Gerber R, Kvasz M, Bergemann R.
Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model.

Diabetes Technol Ther. 2006 Apr;8(2):219-36.

Casciano RN, Walzer S, Mueller E.
Krankheitsmodell am Beispiel Diabetes - das EAGLE-Modell

[Eagle - an example for a diabetes simulation model]. Gesund.ökon. Qual manag Supplement 2, 2005; 10: S64-S69

Health Policy / Pricing

Walzer S, Gerber-Grothe A, John J, Rogowski W 

Vergütungshöhe und Preissetzung [Reimbursement level and pricing]

in Rogowski W. Business Planning im Gesundheitswesen. Springer Gabler. 2016. Chapter 9. 205 - 234

Schwander D, Banz K, Kaier K, Walzer S 

Evaluation of a possible predictor for Federal Joint Committee decisions on early benefit assessments according to the German act on the reform of the market for medicinal product 
Health Policy 2014 Sept; 117(3): 334-344

Walzer S, Droeschel D 

Sind Unvollständigkeiten vermeidbar? [Is incompleteness in the context of AMNOG avoidable?] 

Market Access & Health Policy 2014; 6: 16-18


Walzer S, Droeschel D. 

Mischpreise im Kontext des AMNOG [Mixed pricing in the context of AMNOG].
Market Access & Health Policy 2014; 3: 23-25

Walzer S, Annemans L, Parow D, Zoellner Y, Shekarriz S, Antonanzas F.
The German AMNOG and its current potential implications on the Spanish and Belgian pricing and reimbursement decisions
.
Journal of Health Policy and Outcomes Research 2013. doi: 10.7365/JHPOR.2013.3.6

Walzer S, Kogels E, Schwander B, Nuijten M.
Pharmaceutical premium price strategy: what could be applied by the medical nutrition industry?

Agro FOOD Industry Hi Tech, Vol. 24(2) - March/April 2013: 39-43

Walzer S, Nuijten M, Wiesner C, Kaier K, Johansson P-O, Oertel S.
Microeconomic surplus in healthcare: Applied economic theory in healthcare in four European countries.

Front. Pharmacol. 2013; 4:17. doi:10.3389/fphar.2013.00017

de Castro Carpeño J, Castro Gómez AJ, Stanisic S, Walzer S.
Is there Value in Using Bevacizumab in Metastatic Non-Small Cell Lung Cancer?

Cancer & Chemotherapy Rev. 2011;6 (3)

Indirect Treatment Comparison

Nuijten MJ, Aultman R, Carpeño Jde C, Vergnenègre A, Chouaid C, Walzer S, Siebert U.
An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.

Curr Med Res Opin. 2011 Nov; 27(11): 2193-201. Epub 2011 Oct 4

Chang GC, Ahn MJ, Wright E, Kim HT, Kim JH, Kang JH, Kim SW, Sherman S, Walzer S.
Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes.

Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:34-40

Chang JW, Thongprasert S, Wright E, Tsang K, Kim HT, Ahn MJ, Kim JH, Kang JH, Kim SW, Walzer S.
An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia.
Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:13-21

Mickisch GH, Schwander B, Escudier B, Bellmunt J, Maroto P, Porta C, Walzer S, Siebert U:
Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy
;
Clinicoecon Outcomes Res. 2011;3:19-27. Epub 2011 Jan 25.

Nuijten M, Heigener DF, Bischoff HG, Chouaid C, Vergnenègre A, de Castro Carpeño J, Aultman R, Walzer S, Siebert U.
Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer.

Lung Cancer. 2010 Aug;69 Suppl 1:S4-10. Erratum in: Lung Cancer. 2010 Nov;70(2):230. Lung Cancer. 2010 Aug;69 Suppl 1:S31.

Epidemiology

Walzer S, Travers K, Rieder S, Erazo-Fischer E, Matusiewicz D.
Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey
.
Clinico Economics and Outcomes Research. 2013; 5: 189 - 192

Quality of Life

Juhász E, Kim J-H, Klingelschmitt G, Walzer S.
Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer
.
European Journal of Cancer. 2013. http://dx.doi.org/10.1016/j.ejca.2012.11.006

Systematic Literature Search

Walzer S, Droeschel D, Nuijten M, Chevrou-Séverac H.
Health economics evidence for medical nutrition: are these interventions value for money in integrated care?
ClinicoEconomics and Outcomes Research 2014; 6: 241-252

Walzer S, Droeschel D, Nuijten M, Chevrou-Séverac H.
Health economic analyses in medical nutrition: a systematic literature review.
ClinicoEconomics and Outcomes Research 2014; 6: 109-124

Conjoint Analysis

Walzer S.
What do parents want from their child's asthma treatment?

Ther Clin Risk Manag. 2007 Mar;3(1):167-75.

Walzer S, Zweifel P.
Willingness-to-pay for caregivers of children with asthma or wheezing conditions.

Ther Clin Risk Manag. 2007 Mar;3(1):157-65.

Hitchcock W, Mellon M, Memran M, Parasuraman B, Ramachandran S, Walzer S.
Caregiver preferences for pediatric asthma treatment delivery systems.

Adv Ther. 2007 Nov-Dec;24(6):1240-53.